CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue
Housing	$ 0	$ 0	$ 0	$ 142,200
Commercial rental - related party	0	0	0	0
Tissue array products	138,727	112,407	289,879	212,317
Total revenue	138,727	112,407	289,879	354,517
Cost of Sales
Housing	0	0	0	123,306
Commercial rental - related party	4,566	16,414	21,262	32,880
Tissue array products	84,815	65,120	183,335	144,434
Total cost of sales	89,381	81,534	204,597	300,620
Gross Profit	49,346	30,873	85,282	53,897
Operating Expenses:
Salaries and wages	42,050	50,316	95,963	102,560
Depreciation and amortization	5,991	36,561	39,436	75,008
Estimates of loss contingencies	0	0	0	27,214
Professional fees	14,457	19,026	54,564	37,735
Selling and distribution expenses	1,918	1,374	6,104	2,753
Other general and administrative expenses	107,485	35,526	141,707	54,854
Total Operating Expenses	171,901	142,803	337,774	300,124
Loss from Operations	(122,555)	(111,930)	(252,492)	(246,227)
Other Income (Expense)
Interest expenses	(61,610)	(46,132)	(107,798)	(92,122)
Other income (expense), net	26,614	3,496	24,566	(22,561)
Total Other Expense, Net	(34,996)	(42,636)	(83,232)	(114,683)
Loss before Income Taxes	(157,551)	(154,566)	(335,724)	(360,910)
Income Tax Expense	142	162	284	162
Net loss	(157,693)	(154,728)	(336,008)	(361,072)
Less: Net loss attributable to the non-controlling interests	(32,442)	(29,860)	(63,935)	(68,325)
Net loss attributable to CYBRDI, INC.	(125,251)	(124,868)	(272,073)	(292,747)
Foreign currency translation loss	33,685	(52,569)	(3,409)	(56,429)
Comprehensive loss	$ (91,566)	$ (177,437)	$ (275,482)	$ (349,176)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	120,225,323	120,225,323	120,225,323